Download Files:
Debio 0932
SKU
HY-13469-10 mg
Category Reference compound
Tags Cancer, Cell Cycle/DNA Damage;Metabolic Enzyme/Protease, HSP
$132 – $1,020
Products Details
Product Description
– Debio 0932 (CUDC-305) is an orally active HSP90 inhibitor, with IC50s of 100 and 103 nM for HSP90α and HSP90β, respectively[1].
Web ID
– HY-13469
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C22H30N6O2S
References
– [1]Bao R, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 2009 Jun 15;15(12):4046-57.|[2]Stenderup K, et al. Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model. Acta Derm Venereol. 2014 Nov;94(6):672-6.|[3]Bao R, et al. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 2009 Dec;8(12):3296-306.
CAS Number
– 1061318-81-7
Molecular Weight
– 442.58
Compound Purity
– 99.97
SMILES
– NC1=NC=CC2=C1N=C(SC3=C(N(C)C)C=C(OCO4)C4=C3)N2CCNCC(C)(C)C
Clinical Information
– Phase 1
Research Area
– Cancer
Solubility
– DMSO : 75 mg/mL (ultrasonic)
Target
– HSP
Isoform
– HSP90
Pathway
– Cell Cycle/DNA Damage;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.